Lack of effect of lacosamide on the pharmacokinetic and pharmacodynamic profiles of warfarin

Epilepsia

Volumn 54, Issue 7, 2013, Pages 1161-1166

  Stockis, Armel ^a   Van Lier, Jan Jaap ^b   Cawello, Willi ^a   Kumke, Thomas ^a   Eckhardt, Klaus ^a  

^a UCB PHARMA   (Belgium)

^b PRA Health Sciences   (Netherlands)

Author keywords

Antiepileptic drug; Lacosamide; Pharmacodynamics; Pharmacokinetics; Warfarin

Indexed keywords

HARKOSERIDE; PROTHROMBIN; WARFARIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN EXPERIMENT; INTERNATIONAL NORMALIZED RATIO; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTHROMBIN TIME; SINGLE DRUG DOSE;

ANTIEPILEPTIC DRUG; LACOSAMIDE; PHARMACODYNAMICS; PHARMACOKINETICS; WARFARIN;

ACETAMIDES; ADULT; ANTICOAGULANTS; ANTICONVULSANTS; AREA UNDER CURVE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FOLLOW-UP STUDIES; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; TIME FACTORS; WARFARIN;

EID: 84879759369     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/epi.12192     Document Type: Article

References (36)

1. Aithal GP, Day CP, Kesteven PJ, Daly AK,. (1999) Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353: 717-719.
2. Benet LZ, Hoener BA,. (2002) Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 71: 115-121.
3. Bergey GK,. (2004) Initial treatment of epilepsy: special issues in treating the elderly. Neurology 63: S40-S48.
4. Bergey G, Birnbaum A, Caserta F, Ferrendelli J, French J, Leppik I,. (2006) Diagnosis and treatment selection in elderly patients with epilepsy. Adv Stud Med 6: 195-209.
5. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T,. (2007) Progress report on new antiepileptic drugs: a summary of the Eighth Eilat Conference (EILAT VIII). Epilepsy Res 73: 1-52.
6. Bockbrader HN, Wesche D, Miller R, Chapel S, Janiczek N, Burger P,. (2010) A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet 49: 661-669.
7. Brodie MJ, Mintzer S, Pack AM, Gidal BE, Vecht CJ, Schmidt D,. (2013) Enzyme induction with antiepileptic drugs: cause for concern? Epilepsia 54: 11-27.
8. Cawello W, Bonn R,. (2012) No pharmacokinetic interaction between lacosamide and valproic acid in healthy volunteers. J Clin Pharmacol 52: 1739-1748.
9. Cawello W, Nickel B, Eggert-Formella A,. (2010) No pharmacokinetic interaction between lacosamide and carbamazepine in healthy volunteers. J Clin Pharmacol 50: 459-471.
10. Cawello W, Surmann E, Waitzinger J,. (2012) Lacosamide has no effect on the enzymatic activity of CYP3A4. Neurology 78:P01.073.
11. Cawello W, Bökens H, Nickel B, Andreas JO, Halabi A,. (2013) Tolerability, pharmacokinetics, and bioequivalence of the tablet and syrup formulations of lacosamide in plasma, saliva, and urine: saliva as a surrogate of pharmacokinetics in the central compartment. Epilepsia 54: 81-88.
12. D'Andrea G, D'Ambrosio R, Margaglione M,. (2008) Oral anticoagulants: pharmacogenetics relationship between genetic and non-genetic factors. Blood Rev 22: 127-140.
13. Dean L,. (2012) Warfarin therapy and the genotypes CYP2C9 and VKORC1. National Center for Biotechnology Information (US), Bethesda, MD. Medical Genetics Summaries [Internet]. Available at: http://www.ncbi.nlm.nih.gov/books/ NBK84174/.
14. Frey R, Muck W, Kirschbaum N, Kratzschmar J, Weimann G, Wensing G,. (2011) Riociguat (BAY 63-2521) and warfarin: a pharmacodynamic and pharmacokinetic interaction study. J Clin Pharmacol 51: 1051-1060.
15. Gidal BE,. (2006) Drug absorption in the elderly: biopharmaceutical considerations for the antiepileptic drugs. Epilepsy Res 68 (Suppl. 1): S65-S69.
16. Gidal BE, French JA, Grossman P, Le Teuff G,. (2009) Assessment of potential drug interactions in patients with epilepsy: impact of age and sex. Neurology 72: 419-425.
17. Huhtakangas J, Tetri S, Juvela S, Saloheimo P, Bode MK, Hillbom M,. (2011) Effect of increased warfarin use on warfarin-related cerebral hemorrhage: a longitudinal population-based study. Stroke 42: 2431-2435.
18. Johnson JA, Gong L, Whirl-Carrillo M, Gage BF, Scott SA, Stein CM, Anderson JL, Kimmel SE, Lee MT, Pirmohamed M, Wadelius M, Klein TE, Altman RB,. (2011) Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther 90: 625-629.
19. Keeling D, Baglin T, Tait C, Watson H, Perry D, Baglin C, Kitchen S, Makris M,. (2011) Guidelines on oral anticoagulation with warfarin-fourth edition. Br J Haematol 154: 311-324.
20. Kramer G, Tettenborn B, Klosterskov Jensen P, Menge GP, Stoll KD,. (1992) Oxcarbazepine does not affect the anticoagulant activity of warfarin. Epilepsia 33: 1145-1148.
21. Kwan P, Brodie MJ,. (2006) Combination therapy in epilepsy: when and what to use. Drugs 66: 1817-1829.
22. Levy RH, Collins C,. (2007) Risk and predictability of drug interactions in the elderly. Int Rev Neurobiol 81: 235-251.
23. Malhotra B, Alvey C, Gong J, Li X, Duczynski G, Gandelman K,. (2011) Effects of fesoterodine on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. Br J Clin Pharmacol 72: 257-262.
24. Oberwittler H, Hirschfeld-Warneken A, Wesch R, Willerich H, Teichert L, Lehr KH, Ding R, Haefeli WE, Mikus G,. (2007) Significant pharmacokinetic and pharmacodynamic interaction of warfarin with the NO-independent sGC activator HMR1766. J Clin Pharmacol 47: 70-77.
25. Patsalos PN, Perucca E,. (2003) Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol 2: 473-481.
26. Perucca E,. (2006) Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 61: 246-255.
27. Pugh MJ, Cramer J, Knoefel J, Charbonneau A, Mandell A, Kazis L, Berlowitz D,. (2004) Potentially inappropriate antiepileptic drugs for elderly patients with epilepsy. J Am Geriatr Soc 52: 417-422.
28. Ragueneau-Majlessi I, Levy RH, Meyerhoff C,. (2001) Lack of effect of repeated administration of levetiracetam on the pharmacodynamic and pharmacokinetic profiles of warfarin. Epilepsy Res 47: 55-63.
29. Rolan PE,. (1994) Plasma protein binding displacement interactions-why are they still regarded as clinically important? Br J Clin Pharmacol 37: 125-128.
30. Stephen LJ,. (2003) Drug treatment of epilepsy in elderly people: focus on valproic acid. Drugs Aging 20: 141-152.
31. UCB (2011a) VIMPAT® (Lacosamide) prescribing information. UCB, Inc., Smyrna, GA, USA.
32. UCB (2011b) VIMPAT® summary of product characteristics for lacosamide. UCB Pharma, S.A., Brussels, Belgium.
33. Vaz-da-Silva M, Almeida L, Falcao A, Soares E, Maia J, Nunes T, Soares-da-Silva P,. (2010) Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study. Clin Ther 32: 179-192.
34. Waterhouse E, Towne A,. (2005) Seizures in the elderly: nuances in presentation and treatment. Cleve Clin J Med 72 (Suppl. 3): S26-S37.
35. Yin OQ, Gallagher N, Fischer D, Zhao L, Zhou W, Leroy E, Golor G, Schran H,. (2011) Effects of nilotinib on single-dose warfarin pharmacokinetics and pharmacodynamics: a randomized, single-blind, two-period crossover study in healthy subjects. Clin Drug Investig 31: 169-179.
36. Yoon HW, Giraldo EA, Wijdicks EF,. (2011) Valproic acid and warfarin: an underrecognized drug interaction. Neurocrit Care 15: 182-185.